Home > Boards > US Listed > Biotechs >

Tonix Pharmaceuticals Holding Corp (TNXP)

TNXP RSS Feed
Add TNXP Price Alert      Hide Sticky   Hide Intro
Moderator: mick, daleb2130, Viewmont, UOENO
Search This Board: 
Last Post: 3/5/2021 4:38:28 PM - Followers: 246 - Board type: Free - Posts Today: 0


$TNXP 12-07-2020 Tonix Pharmaceuticals is enrolling participants in a 
Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit 

http://www.RALLYStudy.com or 
http://www.clinicaltrials.gov (NCT04508621).
https://www.tonixpharma.com/
Latest News
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia • December 7, 2020 • 7:00 AM EST


06-20-2020 T-CELL THEORY INSIDE T-CELL KILLS VIRUS FROM WITHIN !!!!!
$TNXP DIRECTORS, ONTRACK FOR T-CELLS. I WAS WATCHING FOX T.V. AND T-CELLS

ATTACK VIRUS FROM WITHIN NOT OUTSIDE OF CELLS.

Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19

Results Expected to Support Tonix’s Anticipated Regulatory Filings for
TNX-1800, a Live Replicating Virus Vaccine Designed to Elicit T Cell Immunity in Addition to Antibodies

THIS COULD BE HUGE HERE FOR THIS PLATFORM !!!!!

https://finance.yahoo.com/news/tonix-pharmaceuticals-southern-research-announce-110010137.html
$NK DOES THIS ONLY ONE DOING VIRUS FROM INSIDE T-CELL PER  Interview with Dr. Patrick Soon-Shiong 

06-20-2020

NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company),
a clinical-stage biopharmaceutical company, announced today an expansion of its strategic collaboration with Southern Research to include a study of

T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. 
The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800,
which is a live replicating virus vaccine designed to protect against COVID-19.  The data will support the interpretation of animal trial results with TNX-1800,
which are expected in the fourth quarter of 2020 and subsequent human trials.

“More than 200 years of vaccine experience, beginning with Dr. Edward Jenner’s landmark discoveries with horsepox and cowpox vaccines, have shown that
T cell eliciting vaccines are particularly effective against viruses,” said Seth Lederman, M.D., President and CEO of Tonix. 
“We believe that protective vaccines against the SARS-CoV-2 virus will be similar in that regard. 
The data we plan to collect from recovered and asymptomatic COVID-19 volunteers will inform vaccine development on how to safely
provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection. 
If approved by the U.S. Food and Drug Administration (FDA) for use in healthy, non-pregnant adults without moderate or severe eczema,

TNX-1800 would feature single-dose immunity without the use of adjuvants, ease of manufacturing on readily available systems,
and glass-sparing distribution since we believe 100 doses of TNX-1800 could be packaged in a single vial.
Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.”

ON FOX T.V.MARIA INTERVIEW  CEO OF $ NK---Soon-Shiong is also the CEO of the Nantworks 
NantKwest (NK)
Dr. Patrick-Soon-Shiong Wikipedia Bio

Forbes Profile   Patrick Soon-Shiong

Excellent Interview    Larry King Live 
 

They have the technology     NantKwest   T-CELL THEORY FROM WITHIN THE T-CELL

Tonix Pharmaceuticals Holding Corp :
06-20-2020
$TNXP DIRECTORS, ONTRACK FOR T-CELLS. I WAS WATCHING FOX T.V. AND T-CELLS

ATTACK VIRUS FROM WITHIN NOT OUTSIDE OF CELLS.

 
$TNXP; Financials=As of May 11, 2020, the Company has an aggregate of 52,302,475 shares of common stock outstanding.

$TNXP
As of March 31, 2020, the Company had cash and cash equivalents of $30.7 million, compared to $11.2 million at December 31, 2019. 
The Company had no debt outstanding at March 31, 2020.
Debt/Eq 0.00-LT Debt/Eq 0.00, Employees 16
Book/sh 1.52, 52W Range 0.39 - 24.90, SELLING 1/2 X'S BOOK.
[BUYER] Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4

LEDERMAN SETH Chief Executive Officer Dec 03 Buy 1.16 20,000 23,180 23,267 Dec 04 07:00 AM

https://finviz.com/quote.ashx?t=TNXP
 

Attractive Product with $650 Million Potential !

Tonix Pharmaceuticals Holding Corp (TNXP)

HUGE NEWS!
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)

TNXP Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL 

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX...

 
Stockholders' equity:    
Preferred stock:
5,000,000 shares authorized Series A Convertible Preferred stock, 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively

 
   
Common stock:
150,000,000 shares authorized;
6,338,320 and 3,251,970 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, and 23,792 and 1,758 shares to be issued as of June 30, 2019 and December 31, 2018, respectively
 

Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-005974/0001387131-19-005974.pdf


On October 31, 2019, the Company filed a Certificate of Change with the Nevada Secretary of State, which was effective November 1, 2019. Pursuant to the Certificate of Change, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 15,717,402 outstanding shares of the Company’s common stock were exchanged for 1,575,246 shares of the Company’s common stock. In connection with the reverse stock split, the Company issued an additional 3,457 shares of the Company’s common stock due to rounding. Furthermore, pursuant to the Certificate of Change, the number of authorized shares of common stock was reduced from 150 million to 15 million. All per share amounts and number of shares in the condensed consolidated financial statements and related notes have been retroactively restated to reflect the reverse stock split.

Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-008474/0001387131-19-008474.pdf


 
   
 

Financials

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
June 30, 2019 Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 12,150 $ 25,034
 

Website
https://www.tonixpharma.com

 

Investor Presentations
https://ir.tonixpharma.com/investor-presentations

Overview





http://www.amazonaws.com
 



Summary

Phase 3 development of new bedtime treatment for PTSD, including militaryrelated PTSD
• Major unmet need; ~12 million Americans annually
• Benefited from FDA 505(b)(2) NDA approval requirement

Complimentary day-time PTSD treatment in development
• Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution

Fibromyalgia bedtime treatment in development
• New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
• TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication

New indication in development for agitation in Alzheimer’s Disease
• Unmet medical need, no approved drug available
• Fast Track Phase 2/3 ready program

Innovative vaccine in development to prevent Smallpox
• Opportunity to supply stockpiling requirement; short development path
• Studies in mice suggest improved safety profile



Conclusion and Valuation

The U.S. military’s intense interest in identifying safe and effective PTSD treatments is important for Tonix, as the AtEase study is the only controlled clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated in the HONOR study (and Tonmya® gets approved), the Department of Defense and the VA would likely be very interested in getting the treatment to military personnel and veterans who suffer from PTSD.

Our valuation for Tonix is derived from a probability adjusted discounted cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximately 8.6 million individuals in the U.S. who suffer from PTSD, it’s estimated that approximately 20% seek treatment. With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probability of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable fully diluted share count of 8.1 million shares leads to a valuation of approximately $13 per share.


Insider & Institutional Ownership :

Rosalind Advisors, Inc. 553 908
Baker Bros. Advisors LP 510 922
B. Riley Capital Management LLC 378 138
Opaleye Management, Inc. 370 000
Empery Asset Management LP 315 000
The Vanguard Group, Inc. 184 377
Heights Capital Management, Inc. 89 713
Seth Lederman, MD 83 400
Ernest Mario, PhD 69 718
Kingdon Capital Management LLC 64 549

-----------------------

IR Contact Information

Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com

---------------------------

If you guys want that the stock moving even faster then put your shares on high GTC sell order like $10
this helps to prevent your shares from being shorted and more important your shares wouldnt be available
on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news.
This works good especially on stocks like TNXP which has only 10 million shares outstanding.
Thank you

How to Prevent your Shares Holdings from being Shorted

http://www.contracts-for-difference.com/Borrowing-lending-shares.html

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PARTNER
LINKS, https://southernresearch.org/drug-development/

https://southernresearch.org/drug-discovery/

https://southernresearch.org/engineering/

https://southernresearch.org/eande/

https://southernresearch.org/medtech/

https://southernresearch.org/stem/

https://southernresearch.org/events/

https://southernresearch.org/newsletter/

https://southernresearch.org/magazine/

https://southernresearch.org/news/category/cancer-research/
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

2,$TNXP,from website. Southern Research, Tonix team to develop potential vaccine against new coronavirus
FEBRUARY 26, 2020 | BY JERRY UNDERWOOD | DRUG DEVELOPMENT
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp.,
a clinical-stage biopharmaceutical company, to support the development of a vaccine, […]

https://southernresearch.org/drug-development/





TNXP Daily Chart



TONIX PHARMACEUTICALS HOLDING CORP. 8-K

https://www.sec.gov/Archives/edgar/data/1430306/000138713120003042/ex99-1.htm









https://finviz.com/quote.ashx?t=tnxp&ty=c&ta=1&p=d





https://www.otcmarkets.com/stock/TNXP/disclosure

https://www.otcmarkets.com/stock/TNXP/news

https://www.otcmarkets.com/stock/TNXP/security
Market Cap Market Cap 100,072,086
Authorized Shares..400,000,000
Outstanding Shares168,585,050

https://www.otcmarkets.com/stock/TNXP/profile

https://www.otcmarkets.com/stock/TNXP/quote

https://www.otcmarkets.com/stock/TNXP/overview

 

DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


 






 

 
TNXP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TNXP News: Current Report Filing (8-k) 03/04/2021 07:05:48 AM
TNXP News: Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement 03/04/2021 07:00:00 AM
TNXP News: Current Report Filing (8-k) 03/03/2021 08:08:58 AM
TNXP News: Current Report Filing (8-k) 02/26/2021 05:37:20 PM
TNXP News: Statement of Changes in Beneficial Ownership (4) 02/25/2021 05:55:25 PM
PostSubject
#7615  Sticky Note 'PATENT $TNXP Tonix Pharmaceuticals received a Notice of Viewmont 02/04/21 08:16:17 AM
#7276  Sticky Note $TNXP Tonix Pharmaceuticals to Host Live Webinar: Antibody mick 11/30/20 11:05:44 AM
#7690   * * $TNXP Video Chart 03-05-2021 * * ClayTrader 03/05/21 04:38:28 PM
#7689   TNXP in accumulate zone MrGlasses 03/04/21 10:29:53 PM
#7688   UOENO, I know. I was trying to show XWAVXALMIMAN 03/04/21 06:44:12 PM
#7687   Relax my dude. I doubt there is a UOENO 03/04/21 12:42:29 PM
#7686   This really sucks! TNXP is going to zero. XWAVXALMIMAN 03/04/21 12:31:12 PM
#7685   Dont let me stop you! UOENO 03/03/21 11:31:49 PM
#7684   UOENO, I know it’s not technically dilution but XWAVXALMIMAN 03/03/21 11:07:48 PM
#7683   I stopped reading after you started talking about UOENO 03/03/21 10:52:56 PM
#7682   I got my proxy today from Ameritrade. Why XWAVXALMIMAN 03/03/21 10:37:46 PM
#7681   Ahhhh daleb2130 03/02/21 11:39:51 PM
#7680   It was sent snail mail not email. It XWAVXALMIMAN 03/02/21 11:07:20 PM
#7679   Maybe it went to the juke email. daleb2130 03/02/21 10:52:01 PM
#7678   I got an email a couple of weeks daleb2130 03/02/21 10:50:32 PM
#7677   raising the AS from 400m to 800m and UOENO 03/02/21 02:40:23 PM
#7676   Anyone know about proxy votes? I got a XWAVXALMIMAN 03/02/21 01:29:37 PM
#7675   He is not a bot. He puts stockmavin 02/27/21 05:07:38 AM
#7674   TNXP 8k who is Jessica Morris and wtf stockticks 02/26/21 11:10:58 PM
#7673   This clay trader feller is quite annoying, is MrKizer 02/26/21 11:10:01 PM
#7672   * * $TNXP Video Chart 02-26-2021 * * ClayTrader 02/26/21 04:42:06 PM
#7671   Tonix Pharmaceutical (TNXP) mick 02/21/21 02:48:40 PM
#7670   Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Receives License From A1stockman 02/19/21 09:00:54 AM
#7669   * * $TNXP Video Chart 02-18-2021 * * ClayTrader 02/18/21 05:39:44 PM
#7668   * * $TNXP Video Chart 02-16-2021 * * ClayTrader 02/16/21 06:05:57 PM
#7667   marks 10 days over $ 1! Frankestin 02/16/21 04:56:26 PM
#7666   Tonix in ClinicalTrials.gov MrGlasses 02/14/21 09:05:16 AM
#7665   * * $TNXP Video Chart 02-12-2021 * * ClayTrader 02/12/21 04:08:04 PM
#7664   * * $TNXP Video Chart 02-11-2021 * * ClayTrader 02/11/21 05:30:59 PM
#7663   $2.14 AH daleb2130 02/11/21 04:18:50 PM
#7662   Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, A1stockman 02/11/21 07:14:57 AM
#7661   * * $TNXP Video Chart 02-10-2021 * * ClayTrader 02/10/21 04:53:59 PM
#7660   TNXP will soar to 10 if we live Iron heart 02/10/21 09:07:18 AM
#7659   No problem- I should have checked the news antman 02/09/21 11:09:41 PM
#7658   I’m sorry antman. I’ve been on these boards XWAVXALMIMAN 02/09/21 10:56:29 PM
#7655   * * $TNXP Video Chart 02-09-2021 * * ClayTrader 02/09/21 05:46:58 PM
#7654   83M traded already...the chart looks ready to go Nealio 02/09/21 11:26:03 AM
#7653   I'm not short- I bought it in the antman 02/09/21 11:12:30 AM
#7652   Dropping hard today?. I don’t think so XWAVXALMIMAN 02/09/21 11:05:45 AM
#7651   Great article. Read and reread this paragraph: XWAVXALMIMAN 02/09/21 11:01:21 AM
#7650   It is dropping hard today - darn antman 02/09/21 10:54:53 AM
#7649   $TNXP is continuing its run for the top AlphaStockNews 02/09/21 08:58:58 AM
#7648   $TNXP Plans To Develop COVID-19 Skin Test. Viewmont 02/09/21 08:29:04 AM
#7647   Its no fallacy he looks like a turtle BuddFoxx006 02/09/21 07:20:54 AM
#7646   That's a I-Hub Fallacy. He was here on daleb2130 02/08/21 10:22:32 PM
#7645   Looks like the turtle is here BuddFoxx006 02/08/21 07:26:58 PM
#7644   * * $TNXP Video Chart 02-08-2021 * * ClayTrader 02/08/21 05:17:23 PM
#7643   $1.67 now AH.s daleb2130 02/08/21 04:59:16 PM
#7642   Excellent news that we are staying at 1.52 XWAVXALMIMAN 02/08/21 02:54:31 PM
#7641   You have to remember they are building 2 daleb2130 02/08/21 11:07:47 AM
#7640   It just means the new low is $1.20. daleb2130 02/08/21 11:05:23 AM
#7639   dilution on every pop nuclear profitz 02/08/21 10:52:29 AM
PostSubject
Consent Preferences